US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
On Friday, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers (PBMs)—CVS Health Inc’s (NYSE:CVS) Caremark, Cigna Corp’s (NYSE:CI) Express Scripts,
FTC sues three largest drug middlemen for allegedly inflating insulin prices
The Federal Trade Commission (FTC) on Friday sued the three largest pharmacy benefit managers (PBMs) for engaging in alleged anticompetitive practices that boosted profits while
FTC sues prescription drug middlemen, alleging they conspired over high insulin costs
The Federal Trade Commission on Friday filed lawsuits against three prescription drug benefit managers or PBMs over concerns the companies are artificially inflating the list price of insulin drugs.
Federal Trade Commission accuses three drug middlemen of inflating insulin prices
The Federal Trade Commission said Friday that it is suing three drug middlemen, accusing them of inflating insulin prices.
High Insulin Prices Spur a Federal Lawsuit Against Three Pharmacy Benefit Managers
The federal government is suing some pharmacy benefit managers over a system of drug rebates that regulators say has made the price of insulin soar for patients
Feds sue pharmacy gatekeepers over high insulin costs
The Federal Trade Commission sued on Friday the three largest pharmaceutical intermediaries charged with negotiating drug prices on behalf of insurers, claiming they are illegally maximizing profits by steering patients to high-cost insulin products.
US FTC sues drug 'gatekeepers' over high insulin prices
The U.S. Federal Trade Commission sued the country's three largest pharmacy benefit managers on Friday, accusing them of steering diabetes patients towards higher priced insulin in order to reap millions of dollars in rebates from pharmaceutical companies.
F.T.C. Accuses Drug Middlemen of Inflating Insulin Prices
The Federal Trade Commission said on Friday that it had taken legal action against the three largest pharmacy benefit managers, accusing the drug middlemen of inflating insulin prices and steering patients toward higher-cost insulin products to increase their profits.
Drug middlemen illegally drive up the cost of insulin, FTC says
Regulators say the nation's largest pharmacy benefit managers are partly to blame for the soaring cost of insulin in the U.S.
FTC sues prescription-drug middlemen over insulin prices, says drugmakers are also ‘on notice’
Pharmacy-benefit managers owned by CVS, Cigna and UnitedHealth “artificially inflated” prices for lifesaving medications, regulator alleges.
KCEN-TV Waco-Temple-Bryan on MSN4d
'It's frustrating' | Brazos Valley man says GLP-1 medications continue to be in short supply for diabetics
The demand for medications like Ozempic continues to cause shortages for both those seeking weight loss and patients with ...
A Guide to Type 2 Diabetes: Symptoms, Causes and Treatments
Type 2 diabetes is characterized by the body's inability to use insulin effectively. Insulin is a hormone that helps regulate metabolism properly. The condition is the most common type of ...
Lohud.com, Westchester County on MSN4d
Do you want to take Wegovy, Ozempic in New York? Are you taking it now? Tell us your story
Nearly 4.4 million adult New Yorkers, or 30%, has obesity, but access to weight-loss medications varies based on a variety of ...
A Common Drug Could Lower Your Dementia Risk By 35 Percent, Research Shows
A new study found a link between SGLT-2 inhibitors and a significantly lower risk of dementia in people with diabetes. Here's ...
FTC Takes Legal Action Against Three Largest PBMs Over High Insulin Prices
Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug ...
The American Journal of Managed Care1d
5 Things Americans Should Know About Weight Loss Drugs
Weight loss drugs have gained attention as a tool to help combat obesity, but understanding how they work, who they’re for, ...
Novo says Ozempic 'very likely' to be on 2027 Medicare negotiation list, Bloomberg News reports
Danish drugmaker Novo Nordisk expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of ...
NC’s Folwell, Sen. Bernie Sanders scrutinize costs of blockbuster weight-loss drugs
In an unconventional alliance, North Carolina State Treasurer Dale Folwell, a Republican, spoke on Capitol Hill at a ...
NJBIZ2d
Novo Nordisk expects Ozempic in next round of Medicare price talks
In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...